An Open-label, Multicenter, Prospective Study of Irreversible Electroporation (Nano Knife) Combined With Radiotherapy and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
This is an open-label, multicenter, prospective study of irreversible electroporation (nano knife) combined with radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer.
Pancreatic Cancer|Locally Advanced Pancreatic Caner
PROCEDURE: Irreversible electroporation
Overall survival, according to RECIST1.1, ±7 days
Time to progress, according to RECIST1.1, ±7 days|progress free survival, according to RECIST1.1, ±7 days|Observe response rate, according to RECIST1.1, ±7 days|disease control rate, according to RECIST1.1, ±7 days|clinical benefit rate, CBR, EOLTC QLQ-C30 (V3.0 Chinese version) was used to evaluate the quality of life (QOL) according to the European Cancer Research and Treatment Organization (EORTC) core quality of life scale, ±7 days
This is an open-label, multicenter, prospective study of irreversible electroporation (nano knife) combined with radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer.